Jump to the top of the page

Showing 530 – 540 of 1157 results

  • Robert Metzger

    View biography for Robert Metzger, Senior Director.

  • Economics Weekly: Restating the Case for Smidcaps

    In this Economics Weekly, Richard de Chazal once again makes the case for why investors should shift their focus toward the long overlooked and underowned smidcap stock.

  • Norwood Medical and Heraeus Transaction

    William Blair acted as exclusive financial advisor to Norwood Medical in connection with its sale to Heraeus.

  • Spotless Brands and Wafra Transaction

    William Blair & Company acted as the exclusive financial advisor to Spotless Brands in connection with its $600 million capital raise, consisting of non-convertible redeemable preferred units, common equity, and first-lien credit.

  • G2V Group and Freshstream Investment Partners transaction

    William Blair acted as the exclusive financial advisor to G2V Group, in connection with its pending sale to Freshstream Investments Partners.

  • William Blair Investment Management Named a 2025 Best Place to Work

    William Blair Investment Management was named a Best Place to Work in Money Management by Pensions & Investments magazine for the 13th year.

  • Leslies Inc Initiation

    William Blair & Company initiated research coverage of Leslie’s Inc. (LESL $21.91). Founded in 1963 and based in Phoenix, Arizona, Leslie’s is the world’s largest omnichannel specialty retailer of swimming pool and spa supplies, services, and repairs for residential and commercial customers.

  • Poshmark Inc Initiation

    William Blair & Company initiated research coverage of Poshmark, Inc. (POSH $66.74), a technology platform and social marketplace where users can buy or sell new or used clothing, shoes, and accessories using its data-driven recommendation engine to drive transactions for its sellers.

  • CarLotz Inc Initiation

    William Blair & Company initiated research coverage of CarLotz, Inc. (LOTZ $9.10). CarLotz is the used car industry’s only consignment-to-retail marketplace, designed to deliver the best deals to both sellers and buyers via its customer-friendly, low-friction platform.

  • Apellis Pharmaceuticals Inc Initiation

    William Blair initiated research coverage of Apellis Pharmaceuticals, Inc. (APLS $27.38), a global biopharmaceutical company focused on treating diseases by controlling the complement cascade.

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures